Cost of supportive care per year for Medicare in the U.S.
$277
Billion
Total cost per patient in the last 5 years of life with dementia.
$287
Thousand
3x higher spent by Medicare on a patient with AD compared to all other seniors.
3x
Managing Alzheimer's disease is currently a significant cost burden.
The New Science of Alzheimer's
Recent breakthroughs in understanding the mechanism of Alzheimer’s disease and the interplay between neurophysiological, cerebral vasculature and neurovascular coupling have emerged.
This interplay is responsible for clearing toxic amyloid and tau waste.
Innovations in microtechnology, material sciences and AI have allowed us to develop unobtrusive, wearable sensors to monitor disease progression.
Continuously monitoring these targets and interventions that engage these targets will enable us to slow or halt disease progression.
Completed internal studies
Clinical Trials
Real-world data
We are validating our platform in clinical trials and with real-world data.
We have validated our device's ability to instrument targets in early studies and are demonstrating our platform's ability to diagnose, predict and slow disease progression in clinical trials.
Our Founders
Paul Dagum, MD PhD
CEO & Co-Founder
Paul is an entrepreneur, physician and computer scientist with a track record of bringing product, technology, and business model innovation in healthcare, cybersecurity and supply chain through four successful venture-backed companies as founder, CSO, CTO and CEO.
Jake Winebaum
Executive Chairman &
Co-Founder
Jake is a serial entrepreneur with a decade-long interest in using connected devices and data to improve work, health, and athletic performance and a history of converting his interests into successful companies across a wide range of industries from media to healthcare.
Our Team & Collaborators
We're a unique team of microtechnology engineers, material scientists, product and industrial designers, mechanical and software engineers, clinical scientists and Alzheimer's neurologists who come from some of the most highly reputed institutions in the nation, as seen here.
Our Scientific Advisory Board
We collaborate with outstanding physician scientists and neuroscientists leading research in neurodegeneration and with pioneering computer scientists and electrical engineers working in AI and microtechnology.
Our Investors
